|Brief Description||Principal Investigator|
|The purpose of this study is to collect biological specimens, including associated demographic and clinical data, from patients with Ewing sarcoma.||Kaplan, Joel Adam|
|The purpose of this trial is to collect biological specimens from patients with osteosarcoma at Children?s Oncology Group (COG) institutions.||Kaplan, Joel Adam|
I. To determine whether denosumab therapy either increases the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to historical Children's Oncology Group (COG) experience or denosumab therapy produces an objective response rate greater than 5% (Cohort 1).
II. To determine whether denosumab therapy increases the disease control rate at 12 months in patients with recurrent resected osteosarcoma as compared to historical COG experience (Cohort 2).
|Kaplan, Joel Adam|
|To determine the disease control rate in patients with completely resected recurrent osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim (GM-CSF) as compared to historical COG experience.||Kaplan, Joel Adam|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
To assess the antitumor activity of nab-paclitaxel combined with gemcitabine in patients with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma using RECIST 1.1 criteria and progression-free survival.
|Oesterheld, Javier E|
|To describe the relationship between absolute lymphocyte count (ALC) 14 days after the start of the first cycle of chemotherapy with 2-year progression-free survival (PFS) rates and other clinical outcome measures in prospectively-treated osteosarcoma patients receiving standard treatment.||Pope, Jennifer Marie|